Active-ingredient Dossier
Etanercept
Active-ingredient Dossier for Etanercept (tumor necrosis factor inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: BRENZYS
- Brand: ENBREL
- Brand: ERELZI
- Brand: NEPEXTO
- Therapeutic area: Immunology
- Therapeutic area: Musculoskeletal
What is
Etanercept Etanercept is a tumor necrosis factor inhibitor.
Australian brands containing
Etanercept — BRENZYS — ENBREL — ERELZI — NEPEXTO
Therapeutic areas
Etanercept is registered in immunology, with four brands available in this therapeutic area.
Sponsor landscape
Four sponsors market etanercept in Australia: Samsung Bioepis AU, Pfizer, Sandoz, and Maxx Pharma.
PBS and regulatory activity
Three brands containing etanercept have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 fiscal year, government expenditure on etanercept was $89,718,166.19 across 108,253 scripts. Four brands have recorded PBAC outcomes, with the latest outcome dated 1 July 2025. Two brands have AusPARs on record, with the latest dated 15 July 2016.